NMPA Cosmetic Filing 2026: New Dossier Requirements & Compliance Guide

The National Medical Products Administration (NMPA) has significantly revised the cosmetic filing and registration process for 2026. Foreign brands exporting skincare, makeup, haircare, or personal care products to China must now adhere to a completely new dossier format, stricter safety assessment rules, and expanded efficacy testing requirements. These NMPA cosmetic filing changes aim to align China’s system with international standards (EU, Japan, ASEAN) while introducing unique local requirements. This guide breaks down every major update and provides a practical roadmap for compliance.

1. New Dossier Structure: Common Technical Document (CTD) Format

The most fundamental change for 2026 is the mandatory adoption of a Common Technical Document (CTD) format for all cosmetic filing dossiers. Previously, Chinese authorities accepted various templates; now all applications must follow a standardized five-module structure similar to pharmaceutical dossiers:

• Module 1: Administrative information and product labels (Chinese-only).
• Module 2: Full ingredient list with CIF (China Ingredient Framework) codes, including fragrance allergens.
• Module 3: Safety assessment report signed by a qualified safety assessor (see section 3).
• Module 4: Efficacy test reports (for functional claims like whitening, anti-aging, sun protection).
• Module 5: Product Information File (PIF) – manufacturing process, stability data, and microbiological test results.

All documents must be submitted electronically via the new NMPA Cosmetic Registration Platform (launched January 2026). Paper submissions are no longer accepted. Foreign applicants must appoint a China-based Responsible Person (RP) to handle the electronic submission – the RP’s digital certificate is required for authentication.

2. Mandatory Safety Assessment by Qualified Chinese Assessor

Previously, foreign brands could submit safety assessments from their own toxicologists or EU‑based assessors. Starting April 1, 2026, all NMPA cosmetic filing applications must include a safety assessment report prepared or co‑signed by a registered Chinese safety assessor. Requirements for the assessor:

• Holds a degree in toxicology, pharmacy, or medicine from a Chinese university (or equivalent with CNAS certification).
• Has at least 5 years of experience in cosmetic safety evaluation.
• Is registered with the NMPA’s new Safety Assessor Database (publicly verifiable).

The safety report must follow the updated Safety Assessment Guidelines (2026 Edition), which now require quantitative risk assessment for 28 priority substances (including preservatives, UV filters, and certain fragrance allergens). For products targeting sensitive populations (children, pregnant women), additional reproductive toxicity data is required. Many foreign brands are now partnering with Chinese contract research organizations (CROs) to fulfill this requirement – lead times for assessor availability are currently 4–6 weeks.

3. Efficacy Testing Strengthened for Functional Claims

China’s cosmetic regulations have always distinguished between “ordinary” (basic cleansing/moisturizing) and “special” cosmetics (whitening, sun protection, anti-hair loss, anti-acne). In 2026, the efficacy testing requirements for special cosmetics have become much more rigorous:

• Whitening claims: Must now include a 12‑week human trial with at least 30 subjects, plus in‑vitro tyrosinase inhibition test.
• Sun protection (SPF/PA): ISO 24444:2025 (in‑vivo) or ISO 24443:2026 (in‑vitro) methods are accepted, but raw data must be uploaded. Previously, only a summary report sufficed.
• Anti‑aging (wrinkle reduction): Clinical evaluation using high‑resolution skin imaging (Visia, PRIMOS) required; self‑assessment questionnaires are no longer sufficient.
• Anti‑hair loss: Requires both phototrichogram analysis (hair count/density) and a dermatologist’s blinded assessment.

For ordinary cosmetics with no functional claims, no efficacy testing is required – but the product label cannot include any performance claims beyond basic function. Many foreign brands have downgraded their claims to “moisturizing” to avoid costly tests. However, if you intend to market a competitive advantage (e.g., “brightening,” “firming”), budget for testing costs of $8,000–$20,000 per SKU.

4. Product Information File (PIF) – Expanded Scope

The Product Information File (PIF) has been expanded under the 2026 rules. Previously, only basic manufacturing and stability data was required. Now, the PIF must include:

• Stability testing: At least three batches tested for 6 months at accelerated conditions (40°C/75% RH) and 12 months at room temperature. Data logs (temperature/humidity charts) must be submitted, not just a summary.
• Microbiological testing: Full panel including total plate count, yeast/mold, and specified pathogens (E. coli, S. aureus, P. aeruginosa). Testing must be performed by a CNAS‑accredited lab.
• Heavy metal testing: New limits: lead ≤ 10 ppm, arsenic ≤ 2 ppm, cadmium ≤ 1 ppm, mercury ≤ 0.5 ppm. ICP‑MS data required.
• Packaging compatibility: Migration studies for any product in direct contact with plastic or metal packaging.

The PIF must be kept on file by the China Responsible Person for at least 5 years after the product’s last batch. NMPA inspectors may request the full PIF during random post‑market checks – failure to produce it within 10 days results in suspension of the filing.

5. Animal Testing – New Alternatives Accepted but Not Fully Abolished

Foreign brands often ask about animal testing. As of 2026, China accepts non‑animal alternative methods (e.g., reconstructed human epidermis for skin irritation, in chemico for phototoxicity) for ordinary cosmetics manufactured in China or imported from countries with certified alternative methods (EU, South Korea, Brazil). However:

• Special cosmetics (whitening, sun protection) still require animal testing for systemic toxicity if no valid non‑animal alternative has been approved by NMPA.
• Imported ordinary cosmetics from countries without recognized alternative methods (e.g., USA, Japan) may still be asked for selected animal tests at the discretion of the reviewer.

Many international brands now manufacture their ordinary products in China (via a contract manufacturer) to bypass import testing, or they work with South Korean labs to produce validation data using OECD‑accepted alternative methods. Consult with a regulatory specialist to determine the optimal strategy for your brand.

6. Timelines and Transition Periods

The NMPA has staggered the implementation of 2026 dossier requirements:

• New filings: From March 1, 2026, all new submissions must follow the CTD format with Chinese safety assessor co‑signature.
• Pending applications (submitted before March 1, 2026): Must supplement the missing Chinese safety assessment by June 30, 2026, otherwise the application will be rejected.
• Existing registered cosmetics: Do not need to re‑file unless you change formula, claims, or manufacturing site. However, the Responsible Person must create an electronic PIF for each registered product by December 31, 2026.
• Renewals: Any cosmetic registration due for renewal after July 1, 2026 must be converted to the CTD format and include all new requirements (full efficacy data, updated safety assessment).

Brands with large portfolios should prioritize high‑revenue SKUs first. The NMPA has indicated that post‑market inspections will focus on products with functional claims, so ordinary cosmetics with no claims face lower immediate risk.

7. Practical Compliance Roadmap for Foreign Brands

To navigate the new dossier requirements for NMPA cosmetic filing, follow this five‑step plan:

1. Appoint a China Responsible Person (RP): The RP must be a legal entity in China with experience in the new electronic platform. Many international brands work with third‑party compliance agencies.
2. Conduct a gap analysis: Compare your existing dossiers (safety, stability, efficacy) against the 2026 CTD requirements. Identify missing tests – especially Chinese safety assessor co‑signature and expanded efficacy data.
3. Commission missing tests: Contact CNAS‑accredited labs in China (e.g., Intertek, SGS, TÜV) for stability, microbiology, and efficacy testing. For safety assessment, contract a registered Chinese toxicologist (fees $1,500–$3,000 per product).
4. Compile the electronic dossier: Use the NMPA’s new submission tool (requires Windows 11 and a USB token). The RP’s digital signature is mandatory.
5. Submit and monitor: After submission, NMPA will issue a preliminary acceptance within 5 working days. Full review takes 3–6 months for special cosmetics, 1–2 months for ordinary cosmetics.

Many foreign brands underestimate the lead time for Chinese safety assessor availability – book your assessor at least 8 weeks before you plan to submit. Additionally, translation of all documents into simplified Chinese must be certified (notarized) if they originate from a foreign authority.

Summary: The 2026 NMPA cosmetic filing reforms represent the biggest change in a decade. Mandatory CTD format, Chinese safety assessor co‑signature, expanded efficacy testing, and digital PIFs create higher barriers but also a more predictable regulatory environment. Foreign brands that invest early in compliance will gain first‑mover advantage. Those who delay face rejected filings, post‑market penalties, or forced withdrawals. Start your gap analysis today – China’s cosmetic market remains the fastest‑growing in the world, but only for the compliant.